

CURRICULUM VITAE

CAROL LEE KOSKI, M.D.

PERSONAL DATA

**APPEARS THIS WAY
ON ORIGINAL**

**APPEARS THIS WAY
ON ORIGINAL**

**APPEARS THIS WAY
ON ORIGINAL**

PROFESSIONAL MEMBERSHIP

American Academy of Neurology.
Maryland Neurology Society.
American Neurology Association.
International Society of Neuroimmunology.
Peripheral Nerve Study Group.
Peripheral Nerve Association.
The Neuropathy Association

HONORS, AWARDS

1974	Postdoctoral Fellowship, Muscular Dystrophy Association (declined).
1976-1981	Teacher Investigator Award, National Institutes of Health.
1991-present	Medical Advisory Board, Guillain Barre Syndrome Foundation International.
1998-present	Medical Liason to Board of Directors, Guillain Barré Syndrome Foundation International

EDITORIAL TASKS

Reviewer for Neurology
Reviewer for Annals of Neurology
Reviewer for Journal of Neuroimmunology
Reviewer for Journal of Neurology (U.K.)
Reviewer for Journal of The Peripheral Nervous System
Reviewer for Journal of Neurological Sciences
Reviewer for Neurogenetics

**APPEARS THIS WAY
ON ORIGINAL**

Carol Lee Koski, M.D.
Curriculum Vitae
Page 4

**MAJOR CONSULTANT AND
MEMBERSHIP ACTIVITIES**

National

1977-1979	Membership Committee, American Academy of Neurology.
1987-1989	Continuing Education Committee, American Academy of Neurology.
1989-1993	S. Weir Mitchell Committee, American Academy of Neurology.
1990-1992	Membership Committee, American Neurology Association.
1988-1992	Neurologic Disorders Program, Project B Committee. National Institute of Health, NINCDS - NIH Study
	Section.
1999, 2000	National Intravenous Immunoglobulin Advisory Panel
2002	Intravenous Immunoglobulin Advisory, Vail Colorado
2002	Intravenous Immunoglobulin, Advisory , Santa Fe
2002- present	Reparative Medicine Study Section, ZRG1 SSS-M, NIH

CAMPUS ACTIVITIES - UMAB

1976-1978	Clinical Years Advancement Committee
1976-1978	Clinical Year Curriculum Committee (Chairman)
1976-1979	Medical Student Advisory Program
1977-1978	Medical School Council Alternate
1981-1984	Medical School Council Representative
1987	OB-GYN Peer Review
1990	Pharmacology Peer Review
1992	Subcommittee on Clinical Dept., Graduate & Continuing Medical Education
1992	Strategic Planning Subcommittee on Faculty Recruitment Development and Retention

1993, 1999 -2000, 2002	SRIS Grant Review
1999-2002	Appointment, Promotion and Tenure Committee
2002	Credentials Committee, UMMS
2001-present	Senator, Faculty Senate for UMAB

Department of Neurology

1977	Report for Accreditation, Role and Critique of Neurology Department
1981-1984	Neurology Grand Rounds
1978-present	Staff attending service, 2 months/year
1976 -present	weekly Neuromuscular Clinic
1984-1987	Interferon Trials in Multiple Sclerosis
1985-1988	Cyclosporine Trial in Multiple Sclerosis
1987-1990	Cyclosporine Trial in Myasthenia Gravis Principal Investigator
1992-present	Neurologic Promotions Committee,
1992-1997	Board Member of Neurology Professional Association
1998-present	Vice president , Neurology PA

TEACHING ACTIVITIES

National and International

April 1986	Dysimmune neuropathies - Seminar, American Academy of Neurology (AAN).
April 1988	Mechanism of Demyelination - Seminar, AAN.
April 1988	Inflammatory Demyelinating Neuropathies, Immunology and Peripheral Neuropathy Courses, AAN.
April 1989	Guillain Barré Syndrome, Immunology Course, AAN
1991 & 1992	Chicago, Boston, and San Diego.
June 1989	Immunopathogenesis of Guillain Barré Syndrome University of London (U.K.).
March 1990	Symposium on Neuroimmunology, Guillain Barré Syndrome, Houston, Texas.

February 1992 February & June 1993 June 1993	"Mechanisms of Demyelination in Guillain Barré Guillain Barré Syndrome with CIPD: Pathogenesis and Inflammatory Neuropathies: Pathogenesis and Treatment, New York University of School of Medicine, Neurology Grand Rounds.
October 1993	"Immunopathogenesis of Guillain Barré Syndrome: Role Kyungpook National University, Taegu, Korea.
November 1993	Guillain Barré Syndrome Foundation International, National Meeting, Baltimore, Maryland. Address on Guillain Barré Syndrome: Pathogenesis.
June 1995	Address on Guillain Barré Syndrome: 2 nd International Congress on Neurorehabilitation.
October 1995	Guillain Barré Syndrome and CIDP: Pathogenesis and Treatment Health Dimension Symposium, Palmspring, CA.
August 1996	Mechanisms of Schwann Cell Damage in Inflammatory Neuropathy". ? Symposium on GBS and Campylobacter NIAID, NIH, Bethesda, MD
November 1996	Rehabilitation Issues in Guillain Barre Syndrome, A SNR's
November 1998	Memorial Lecture: Management of the Guillain Barre Syndrome, Guillain Barre Syndrome Foundation, International Meeting, Dallas
October 1998	Management of CIDP, International Meeting of the Peripheral Neuropathy Association, Greece
April 1999	Mechanisms of Inflammatory Neuropathy, International Congress on Neurorehabilitation, Toronto
September, 1999	Inflammatory Plexopathies. 6 th Workshop of the European CMT consortium, 71 st ENMC International Workshop
July 2000	The Current State of Knowledge on Guillain Barre Syndrome, Instituto de Ciencias Neurologicas, Lima, Peru
August 2000	Immune mediated Neuropathies-Peripheral Neuropathy in the New Millennium. Banff, Canada
November 2000	Management of the Recovering GBS Patient from ICU to Rehab, 6 th International Symposium, Guillain Barré Syndrome Foundation, Washington DC
December 2000	Immune Mediated Neuropathies, NYU Neurology Grand Rounds, New York, NY
July 2001	CIDP, Peripheral Neuropathy in the new Mellenium. Rome, Italy
June 2002	Treatment of CIDP and other Immune Mediated

November 2002 Neuropathies, Santa Fe, NM
Rehabilitation of the GBS Patients, 7th International
Symposium, Guillain-Barré syndrome Foundation, Manhattan
Beach CA

Local Symposia

January 1984 "Incorporation of P_o into Liposomes", Neurochemistry
John Hopkins University Hospital.

June 1984 "Anti-peripheral Myelin Antibodies which Activate
C1 in patients with Guillain Barré Syndrome, Neurology
Grand Rounds, University of Maryland Hospital.

January 1985 Anti-peripheral Nerve Myelin Antibodies in Guillain
Barré Syndrome, Pathology Department, University of
Maryland Hospital, Colloquia in Human Disease.

February 1985 Anti-peripheral Nerve Myelin Antibodies in Guillain
Barré Syndrome and other demyelinating neuropathies,
Neurology Grand Rounds, John Hopkins University
Hospital.

March 1986 Anti-peripheral Nerve Myelin Antibodies in Guillain
Barré Syndrome: Quantitation, kinetics and clinical
correlation - Discussant of Inflammatory Neuropathies
New York Academy of Science, Seventh International
Conference on Myasthenia Gravis.

May 1986 "Role of Complement in Demyelination of Central and
Peripheral Nervous Systems", Department of Neurology
University of Maryland.

June 1989 Guillain Barré Syndrome - Neurology Grand Rounds
Johns Hopkins Hospital.

November 1990 "Guillain Barré Syndrome:, Neuroimmunology Course,
University of Maryland, School of Medicine.

November 1991 "GM1 Ab in Guillain Barré Syndrome", Neuroimmunology
Course, University of Maryland, School of Medicine.

June 1992 Inflammatory Neuropathies - George Washington
University.

September 1992 Guillain Barré Syndrome - Neurology Grand Rounds
Johns Hopkins Hospital.

September 1993 Guillain Barré Syndrome: Pathogenesis and Treatment
Union Memorial Hospital.

November 1993 Guillain Barré Syndrome Medical Grand Rounds, University of
Maryland Hospital.

September 1999	Guillain Barré syndrome. Medical Grand Rounds, Montgomery County Hospital
November, 2000	Subacute Inflammatory Neuropathy, Neuroimmunology CME course, University of Maryland, Baltimore
September 2001	CIDP, Two Decades of Achievement in Neurology, Baltimore Maryland
May, 2002	Pathogenesis of GBS Morgantown, WV
June, 2002	Rehabilitation of the GBS Patient, Morgantown, WV
	New Aspects of Neuromuscular Disease, UMMS

University of Maryland

Graduate School

1977	Histochemistry of Muscle Anatomy Course by Dr. Hall-Craggs Lecture on "Histochemistry of the Human Muscle Biopsy"
1990-present	Adjunct Member, Graduate School faculty Pathology #713 - General Cellular Pathobiology

Student Supervision

Undergraduate Students

1990-1993	
1991-1993	
1991-1992	

Graduate Students

1981-1985	Thesis Committee, Dept. of Pathology
1991-1993	Masters Program
1991-1995	Thesis Committee, Dept. of Pathology
1993-1998	Ph.D. Program

Postdoctoral Fellows

1989-1992
1989-1995
1995-1997
1995-1996
1999-2002
2000-2002
2002-

~~_____~~
~~_____~~
~~_____~~
~~_____~~
~~_____~~
~~_____~~
~~_____~~

Freshman Year

1977-1978	Practical Neurophysiology (EMG) Neuroscience I - 8 sessions.
1986	Literature Discussion, Neuroscience I - 9 hours "Mechanism of Peripheral Nerve Demyelination"
1987	Demyelinating Diseases.
1993	Clinical Correlation Lecture Neurosciences
1993	Guillain Barré Syndrome.
1993-1998	Literature Discussion group, Neurosciences I - Mechanisms of Demyelination - 5 sessions.

Sophomore Year

1976-1985	Introduction to Physical Diagnosis "Neurological Examination" - 6 (2hr.) sessions/year.
1977-1981	Neuropathology Course "Stupor and Coma" "Neuromuscular Disease" Clinical Pathological Correlation "Fungal Meningitis" "Muscular Dystrophy".
1995-present	Small group sessions in "Immunologic Techniques". in Pathophysiology and Therapeutics course. Pathophysiology of Neuromuscular Diseases, Group leader and teacher.
2000	Clinical Correlation and Patient presentation Immunology of Myasthenia Gravis, Pathophysiology and Therapeutics course
2002	Introduction to Peripheral Neuromuscular Disease

Junior Year

1976-1978	Weekly 2 hour lectures, didactic and clinical correlation, Neuroscience III. Director Development, administration and grading of Neuroscience tests. Evaluation of all juniors on neurology rotation.
-----------	---

Neurology residents

1977-1979	Introductory Lecture to Neurology Residents "Metabolic Encephalopathy"
1977 & 1979	Minicourse to Neurology Residents "Histochemistry of Muscle" "Neuromuscular disease"
1976-present	Supervision and Instruction Private Consultations One month per year
1981	Neuropathology - "Biochemical and Immunologic Aspects of Cerebral and Peripheral Myelin"
1977- present	Attending Rounds - 2 months of each year
1990-present	Guillain Barré Syndrome pathogenesis and treatment
1993-	Introduction to Management of Motor Neuropathies
1993- 1998	Neuroanatomy of Touch.
1996-present	Electrophysiology Course , Inflammatory Myopathies diagnosis and pathophysiology Demyelinating Neuropathies Axonal Neuropathies

GRANTS AND CONTRACTS

Glycoprotein and Neuromuscular Interactions. Teacher Investigator Award, National Institutes of Health, 6/76-6/81.

Antigenicity of Peripheral Nerve Myelin. Frank G. Bressler Research Fund: \$ ~~7/76-6/77~~.

Characterization of a Monoclonal Antibody to the P⁰ Glycoprotein of Peripheral Nerve Myelin. Pangborn Fund, ~~1981-1982~~ 1981/1982.

Complement Interaction with Nucleated Cell Membrane. NIDR; \$ _____ 8/1/82-7/31/84.

Mechanisms of Peripheral Nerve Demyelination. ALS/MS Clinical Center Grant, _____ M.D., Principal Investigator - C.L. Koski, Total Award - _____ 12/1/81-11/30/86.

Studies of Human Demyelinating Neuropathies. Pathogenesis of Peripheral Disease - Center Grant _____, Johns Hopkins University - Subcontract to C.L. Koski, Total Award _____ 2/1/86-1/31/91.

Mechanisms of Peripheral Nerve demyelination - MS Demyelinating Center Grant Renewal - _____ Principal Investigator, C.L. Koski, M.D. - Total Project Award _____ over five years, 12/1/86-11/30/91.

Genetic Causes of Mental Retardation - Adrenoleukodystrophy: Phenotype Pathogenesis and Therapy - _____ Kennedy Institute, Baltimore, Maryland - Subcontractor to C.L. Koski - Total Award _____ over five years, 1/1/87-12/31/91.

Role of Forssman Antigen in Peripheral Demyelination - National Multiple Sclerosis Society - Principal Investigator, C.L. Koski, M.D. - Total Award _____ 4/91-3/94.

Mechanisms of Peripheral Nerve Demyelination, Project IV Demyelinating Center Grant renewal - _____ Principal Investigator, C.L. Koski, M.D. - _____, 4/92-3/97.

Mechanisms of Peripheral Nerve Demyelination RO1, PI C.L. Koski, MD, NINDS-NIH, _____, 7/98 - 6/2003

Ovarian hormones and neuronal survival. Pilot Project, PI CLKoski MD, PP0754. National Multiple Sclerosis Society, _____ 9/2000-8/2001.

Progesterone Induced Neuronal Apoptosis in EAE, PI CL Koski M.D. Wadsworth Foundation. _____ 8/1/02-8/1/05.

PUBLICATIONS

Chapters

1. Mayer, R.F. and Koski, C.L.: Treatment of Acute Respiratory Muscle Failure, pp. 181-206, Neurological Emergencies, Recognition and Management. M. Salzman,

Editor, Raven Press, 1980.

2. Koski, C.L.: Guillain Barré Syndrome: In: Neurovirology. Johnson, KP, (editor). Neurologic Clinics. W.B. Saunders Co., 1984.
3. Mayer, R.F., Koski, C.L., and Max, S.R.: Myasthenia Gravis and Disorders of Peripheral Nerve and Muscle. In Recent Achievements in Restorative Neurology 2: Progressive Neuromuscular Diseases. N. Dimitrijevic, B Kakulas, and GB Vrbova (editors) S Carger, Basel. pp. 184-204, 1986.
4. Koski C.L.: Complement-Fixing Antiperipheral Myelin Antibodies and C9 Neoantigen in Serum of Patients with Guillain-Barré Syndrome: Quantification, Kinetics, and Clinical Correlation. Myasthenia Gravis: Biology and Treatment. DB Drachman, editor. Annals of the New York Academy of Science. 505: 319-325.
5. Koski CL, and Khurana R: Acute Polyneuropathies. In Neurological Emergencies, Recognition and Management. M Salcman, Editor, Raven Press. pp. 261-280, 1990.
6. Shin ML and Koski CL: Role of Complement in Demyelination, Myelin, R Martenson, Editor, Plenum Publishing Company. pp 801-831, 1992.
7. Koski CL: Humeral mechanisms in peripheral demyelination. In Peripheral Nerve. P.J. Dyck, Editor, Neurology Clinics, WB Saunders Co, 10:629-649, 1992.
8. Koski CL: Guillain Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy: Pathogenesis and treatment. M Dulakas, Editor, Seminars in Neurology, 14:123-130, 1993.
9. Koski CL: Immune interactions in the peripheral neurons system: in Immune Mediated Neuropathies. N. Latov, J. Kelley, editors. Cambridge University Press, pp 3-35, 1998.

Invited Reviews

1. Koski CL, Khurana RK, and Mayer RF. Guillain Barré Syndrome. American Family Physician. 34: 190-210, 1986.
2. Koski CL Plasmapheresis - A Therapeutic Tool in Neurologic Disorders. MMJ 36: 1035-1037, 1987.

3. Koski CL Guillain Barré Syndrome. Autoimmunity Forum Neurology 1:2-4, 1989.
4. Koski CL: Characterization of anti-peripheral nerve myelin antibodies in Guillain Barré Syndrome. Annals of Neurology 27:(Suppl) 44-47, 1990.
5. Koski CL: Mechanisms of Schwann cell damage in inflammatory neuropathy. Journal of Infectious Diseases. 176 (Suppl 2):169-172, 1997.¹

Papers

1. Koski CL, and Max SR: Substrate Utilization by the Denervated Rat Hemidiaphragm. Exp Neurol, 43:547, 1974.
2. Koski CL, Rifenberick DH, and Max SR: Oxidative Metabolism of Skeletal Muscle in Steroid Atrophy. Arch Neurol, 31: 407, 1974.
3. Rifenberick DH, Koski CL, and Max SR: Metabolic Studies on Skeletal Muscle Regeneration. Exp Neurol, 52: 40, 1976.
4. Wagner KR, Max SR, Grollman EM, and Koski CL: Glycolysis in Skeletal Muscle Regeneration. Exp Neurol, 45:527, 1974.
5. Koski CL, and Kolodny, EH: Phospholipid Analysis of Red Blood Cell Membrane in Duchenne Muscular Dystrophy. Clinical Chemica Acta 85: (3): 295, 1978.
6. Koski CL, and Max SR: Comparison of the protein composition of Myelin of Motor and Sensory Nerves. J Neurochem 34 (2):449, 1980.
7. Vanguri P, Koski CL, and Shin ML: Complement Activation by Myelin: Activation of the Classical Pathway in the Absence of Myelin Specific Antibodies. Proc Natl Acad Sci USA 79: 3290. 1982.
8. Franko MC, Koski CL, and Gibbs CJ, McFarlin DE, and Gajdusek DC: Monoclonal Antibody Specific for Myelin Glycoprotein P₀: Derivation and Characterization. Proc Natl Acad Sci USA 79: 3618, 1982.
9. Koski CL, Ramm LE, Hammer C, Mayer MM, and Shin ML: Cytolysis of Nucleated Cells by Complement: Cell Death Displays Multihit characteristics. Proc Natl Acad Sci USA, 89: 3861, 1983.

10. Ramm, LE, Whitlow M, Koski CL, Shin ML, and Mayer MM: Elimination of complement channels from the plasma membranes of U937, a nucleated mammalian cell line: Temperature dependence of the elimination rate. *J Immunol* 131: 1411-1415, 1983.
11. Koski CL, Franko MC, and Shin ML: Incorporation of P₀ Glycoprotein in Liposomes: Demonstration of a Two Domain Structure by Immunochemical and PAGE Analysis. *J Neurochem* 42: 856-862, 1984.
12. Koski CL, Humphrey R, and Shin ML: Anti-peripheral myelin antibody in patients with demyelinating neuropathy: Quantitative and kinetic determination of serum antibody by complement component 1 fixation. *Proc Natl Acad Sci USA*, 82: 905-909, 1985.
13. Koski CL, Vanguri P, and Shin ML: Activation of the Alternative Pathway of Complement by Human Peripheral Nerve Myelin. *J Immunol* 134: 1810-1814, 1985.
14. Carney DF, Koski CL, and Shin ML: Elimination of Terminal Complement Intermediates from the Plasma Membrane of Erlich Cells: The rate of disappearance differs for cells carrying C5b-7, C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. *J Immunol* 134: 1804-1809, 1985.
15. Koski CL, Gratz E, Sutherland J, and Mayer RF: Clinical Correlation with Anti-Peripheral Myelin Antibodies in Guillain Barré Syndrome. *Ann Neurol*, 19: 573-577, 1986.
16. Sanders ME, Koski CL, Robbins D, Shin ML, Frank MM, and Joiner KA: Terminal Complement Pathway Activation in Cerebrospinal Fluid in Guillain Barré Syndrome and Multiple Sclerosis. *J Immunol*, 136: 4456-4459, 1986.
17. Camenga DL, Johnson KP, Alder M, Engelhardt CD, Fishman PS, Greenstein JI, Haley AS, Hirsch RL, Kleiner JE, Kofie VY, Koski CL, Margulies SL, Panitch HS, and Valero R: Systemic recombinant alpha-2 Interferon Therapy in relapsing Multiple Sclerosis. *Arch Neurol* 43: 1239-1246, 1986.
18. Koski CL, Sanders ME, Swoveland PT, Shin ML, Frank MM, and Joiner K: Activation of Terminal Components of Complement in Patients with Guillain-Barré Syndrome and other Demyelinating Neuropathies. *JCI*, 80:1492-1497, 1987.

19. Sanders ME, Alexander EL, Koski CL, Frank MM, and Joiner K, Detection of Activated Terminal Complement (C5b-9) in Cerebrospinal Fluid from patients with Central Nervous System Involvement of primary Sjogren's Syndrome or Systemic Lupus Erythematosus. J Immunol, 138:2095-2099, 1987.
20. Sanders ME, Alexander EL, Koski CL, Shin ML, Sano Y, Frank MM, and Joiner, KA. Terminal Complement complexes (SC5b-9) in Cerebrospinal Fluid in Autoimmune Nervous System Diseases. Annals NY Academy of Sciences 1988, 540:387-389.
21. Khurana, RK, Koski, CL, and Mayer, RF: Dysautonomia in Lambert-Eaton Myasthenic Syndrome. J Neurol Sci 85: 77-86, 1988.
22. Koski CL, Chou DKH, and Jungalwala FB: Anti-Peripheral Myelin Antibodies bind a Neutral Glycolipid of Peripheral of Peripheral myelin and cross-react with Forssman Antigen. J Clin Invest 84:280-287, 1989.
23. The Multiple Sclerosis Study Group: Efficacy and Toxicity of Cyclosporine in Chronic Progressive Multiple Sclerosis: A Randomized, Double-blind, Placebo-controlled Clinical Trial. Ann Neurol 27:591-605, 1990.
24. Mane SS, Clark MB, and Koski CL: In Vitro Demyelination by Serum from patients with Guillain-Barré Syndrome requires terminal complement complexes. Ann Neurol 29:397-404, 1991.
25. Vriesendorp F, Mayer RF, and Koski CL: Kinetics of Anti-peripheral Nerve antibody in plasmapheresed and non-plasmapheresed patients with Guillain Barré Syndrome. Arch Neurol 48:858-861. 1991.
26. Rudnicki S, Vriesendorp FS, Koski CL, and Mayer RF: Electrophysiologic studies in Guillain-Barré Syndrome; Effect of plasma-exchange and antibody rebound. Nerve and Muscle. 15:57-62, 1992.
27. Vriesendorp F, Dmytrenko G, Dietrich T, and Koski CL: Anti-Peripheral Nerve Myelin Antibodies and Terminal Activation Products of Complement in Serum of Patients with Acute Brachial Plexus Neuropathy. Arch Neurol, 50:1301-1303, 1993.
28. Mishu B, Ilyas AA, Koski CL, Vriesendorp F, Cook SD, Mithen FA, and Blaser MJ: Serologic evidence of preceding Campylobacter jejuni infection in patients with Guillain-Barré syndrome. Annals of Internal Medicine 18:947-953, 1993.

29. Vriesendorp FJ, Mishu B, Blaser M, and Koski CL: Serum antibodies to GM1, GD1b, peripheral nerve myelin and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls; correlation and prognosis. *Ann Neurol* 34:130-135, 1993.
30. Sawant-Mane S, Estep AE and Koski CL: Antibody of patients with Guillain Barré Syndrome mediates complement dependent cytolysis of Rat Schwann cells: Cytolysis reflects Schwann cell phenotype. *J. of Neuroimmunology*. 49:145-152, 1994.
31. Kamin-Lewis R. M., Karasanyi N., Koski C. L., and Lewis G. K. (1994) Adherence-mediated T cell activation in multiple sclerosis and other neurological disorders. *J Neuroimmunol.* 53, 163-171.
32. Vriesendorp F, Mayer RF, Triggs WJ and Koski CL: Electrophysiological Studies in Guillain Barré Syndrome: Correlation with antibodies to GM1, GD1B and compylobacter jejuni. *J. Neurol.*, 242:460-465, 1995.
33. Vriesendorp, F.J., Flynn, R.E., Pappoll, M.A., and Koski, C.L.: Complement depletion affects demyelination and inflammation in experimental allergic neuritis. *J. Neuroimmunol.*, 58:157-165, 1995.
34. Koski, C.L., Estep, A.E., Sawant-Mane,S., Shin, M.L., and Hansch, G.M.: Complement regulatory molecules on human myelin and glial cells: Differential expression affects the deposition of activated complement protein. *J. Neurochem.*, 66:303-312, 1996.
35. Sawant-Mane, S., Piddlesden, S.J., Morgan, B.P., Holers, V.M., and Koski, C.L.: CD59 homologue regulates complement dependent cytolysis of rat Schwann cells. *J. Neuroimmunol.*, 69:63-71, 1996.
36. Chehrenama, M., Zargardo, M.T., and Koski, C.L.: Subarachnoid hemorrhage in a patient with Lyme disease. *Neurology*, 48:520-3, 1997.
37. Dashiell, S., Vanguri, P., and Koski, C.L.: Dibutyryl cyclic AMP and inflammatory cytokines mediate C3 expression in Schwann cells. *Glia*, 20, 308-321, 1997.
38. Vriesendorp FJ, Flynn RE, Pappolla MA, and Koski CL: Soluble complement receptor 1 (SCR1) is not as effective as cobra venom factor in the treatment of experiemental allergic neuritis, *Int J. Neurosci.* 92:287-298, 1997.

39. Lasky T, Tarracciano GT, Magden L, Koski CL, et al. Guillain Barre Syndrome and the influenza vaccines of 1992-93 and 1993-94; *N Engl J Med* 339:1797-802, 1997.
40. Good JL, Cherenama M, Mayer RF, and Koski CL: Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. *Neurology* 51:1735-8, 1998.
41. Ballesteros M., Lasky T., Nash D., Magder L., Koski C. L., and Chehrenama M. (1998) Guillain-Barre syndrome incidence based on hospital discharge data. *J Infect Dis.* 178, 1228.
42. Dashiell SM, Koski CL: Sublytic terminal complement complexes decrease protein zero gene expression in Schwann cells. *J Neurochem* 73:3231-2330, 1999
43. Dashiell SM, Rus H, Koski CL: Terminal Complement Complexes Concomitantly Stimulate Proliferation and Rescue of Schwann Cells from Apoptosis. *Glia* 30:187-98, 2000.
44. Hafer-Macko C, Dyck PJ, and Koski CL. Endoneurial complement activation in acquired and hereditary amyloid neuropathy. *JPNS* 5:131-139, 2000.
45. Hila S, Soane L, Koski CL. Sublytic C5b-9 stimulated Schwann cell survival through PI 3-kinase mediated phosphorylation of BAD. *Glia* 36:58-67, 2001
46. Hoffman G., Le W.W, Murphy AZ, Koski CL, Divergent Effects of Ovarian Steroids on Neuronal Survival during Experimental Allergic Encephalitis in Lewis Rats *Experimental Neurol* 171: 272-284, 2001..
47. Latov N., Chaudhry V., Koski C. L., Lisak R. P., Apatoff B. R., Hahn A. F., and Howard J. F., Jr. Use of intravenous gamma globulins in neuroimmunologic diseases. *J Allergy Clin Immunol.* 108, S126-132, 2001.
48. Koski CL. Therapy of Chronic Inflammatory Demyelinating Polyradiculoneuritis and Related Immune Mediated Neuropathies. *Neurology* 59:S22-7, 2002.
48. C.L Koski*, S. Hila*, G. Hoffman, Ovarian Hormones differentially effect Neuron Death mediated by TNF α via Expression of Anti-apoptotic Proteins and Activation of JNK Pro-apoptotic Signal Cascade. ECTRIM- ACTRIM, Baltimore, 2002.

**APPEARS THIS WAY
ON ORIGINAL**